Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

duration of the PSA progression-free survival

Outcome Time Frame:

open (until therapy end or stop)

Safety Issue:

No

Principal Investigator

Clinical Development Support

Investigator Role:

Study Director

Investigator Affiliation:

Ferring Pharmaceuticals

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

FE200486 CS41

NCT ID:

NCT00930319

Start Date:

June 2009

Completion Date:

December 2014

Related Keywords:

• Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
• Carcinoma
• Prostatic Neoplasms